Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 4Gynecologic 3Thoracic 2Dermatologic 2Sarcoma 1Other hematologic neoplasm 1CNS 1Breast 1

Conditions

Melanoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Nivolumab 24pembrolizumab 22Ipilimumab 17Specimen Handling 15Magnetic Resonance Spectroscopy 9CTLA-4 Antigen 8Opdualag 7relatlimab 6Cyclophosphamide 6binimetinib 5Paclitaxel 5trametinib 4fludarabine phosphate 4fludarabine 4cemiplimab 4Carboplatin 4Biopsy 4lifileucel 3dabrafenib 3atezolizumab 3X-Rays 3Taxes 3Standard of Care 3Radiotherapy 3Radiation 3Pemetrexed 3Introns 3Interferon alpha-2 3Immunoglobulin G 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
lenvatinib × Dermatologic × 30 days × Clear all
NCT04955743 2026-06-04

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled 13 charts
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT04305054 2026-05-28

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
335 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡